Hodgkin's Lymphoma has a very good prognosis. In the unusually refractory patients allogeneic transplantation offers a chance of cure. The so-called checkpoint inhibitors, such as Nivolumab can play a relevant role in this type of patients. Their side effects and usefulness after allogeneic transplantation are under investigation. Relapse after allogeneic transplantation has an extremely poor prognosis. We report two patients with refractory Hodgkin's lymphoma who relapsed after an allogeneic transplant and who were successfully treated with Nivolumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/s0034-98872021001001507 | DOI Listing |
Publication Analysis
Top Keywords
allogeneic transplantation
16
relapse allogeneic
8
hodgkin's lymphoma
8
allogeneic
5
[treatment hodgkin
4
hodgkin disease
4
disease relapse
4
transplantation
4
transplantation nivolumab
4
nivolumab report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!